Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor

Emerging Microbes and Infections

Volumn 2, Issue , 2013, Pages

  Sharma, Geeta ^a   Champalal Sharma, Danilal ^a   Hwei Fen, Leong ^a   Pathak, Mukta ^b   Bethur, Nijaguna ^b   Pendharkar, Vishal ^a   Peiris, Malik ^c   Altmeyer, Ralf ^a,d  

^a CombinatoRx Singapore Pte Ltd ^*  (Singapore)

^b Bruker Singapore Pte Ltd   (Singapore)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

inflammation; influenza; oseltamivir; phospsphodiesterase 4; selective serotonin reuptake inhibitor; therapy

Indexed keywords

INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; ROLIPRAM; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A (H1N1); LUNG ALVEOLITIS; MALE; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84904189874     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2013.52     Document Type: Article

References (36)

1. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-186.
2. Ford SM, Grabenstein JD. Pandemics, avian influenza A (H5N1), and a strategy for pharmacists. Pharmacotherapy 2006; 26: 312-322.
3. Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336: 1534-1541.
4. Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012; 486: 420-428.
5. Russell CA, Fonville JM, Brown AE et al. The potential for respiratory droplettransmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012; 336: 1541-1547.
6. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009; 15: 277-284.
7. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001; 64: 262-268.
8. Traves SL, Proud D. Viral-associated exacerbations of asthma and COPD. Curr Opin Pharmacol 2007; 7: 252-258.
9. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101: 643-649.
10. To KK, Hung IF, Li IW et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50: 850-859.
11. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol 2009; 30: 574-584.
12. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 2009; 106: 3455-3460.
13. Carter MJ. A rationale for using steroids in the treatment of severe cases of H5N1avian influenza. J Med Microbiol 2007; 56: 875-883.
14. Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis 2010; 202: 1161-1170.
15. Garcia CC, Guabiraba R, Soriani FM, Teixeira MM. The development of antiinflammatory drugs for infectious diseases. Discov Med 2010; 10: 479-488.
16. Howard WA, Peiris M, Hayden FG. Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, , USA. Influenza Other Respi Viruses 2011; 5: 453-454, e458-e475.
17. Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther 2011; 9: 807-822.
18. Chan PK, Lee N, Zaman M et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206: 1359-1366.
19. Lee N, Allen Chan KC, Hui DS et al. Effects of early corticosteroid treatment on plasma SARS-associated CoronavirusRNAconcentrations in adult patients. J Clin Virol 2004; 31: 304-309.
20. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105: 8091-8096.
21. Ikemura T, Schwarze J, Makela M et al. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia. J Pharmacol Exp Ther 2000; 294: 701-706.
22. Taler M, Gil-Ad I, Lomnitski L et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007; 17: 774-780.
23. Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 2000; 48: 1-16.
24. Nguyen JT, Hoopes JD, Smee DF et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53: 4115-4126.
25. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199-206.
26. Kubera M, Maes M, Kenis G, Kim YK, Lason W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 2005; 134: 251-258.
27. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol 2001; 16: 95-103.
28. Maes M, Kenis G, Kubera M, de Baets M, Steinbusch H, Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int Immunopharmacol 2005; 5: 609-618.
29. Tremaine LM, Stroh JG, Ronfeld RA. Characterization of a carbamic acid ester glucuronide of the secondary amine sertraline. Drug Metab Dispos 1989; 17: 58-63.
30. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012; 12: 275-286.
31. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155: 308-315.
32. Rennard S, Knobil K, Rabe KF et al. The efficacy and safety of cilomilast in COPD. Drugs 2008; 68(Suppl 2): 3-57.
33. Wedzicha JA, Rabe KF, Martinez FJ et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013; 143: 1302-1311.
34. Govorkova EA, Marathe BM, Prevost A, Rehg JE, Webster RG. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res 2011; 91: 81-88.
35. Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S, Noah DL. Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sci 2012; 90: 440-445.
36. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-851.